Drug metabolism in human liver microsomes assessed as (R)-4-fluoro-5-(6-(2-hydroxypropoxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-4-yloxy)-1H-indole-2-carboxylic acid formation at 2 uM for 60 mins by LC/MS analysis
Drug metabolism in human liver cytosol assessed as (R)-4-fluoro-5-(6-(2-hydroxypropoxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-4-yloxy)-1H-indole-2-carboxylic acid formation at 2 uM for 60 mins by LC/MS analysis in presence of NADPH
Drug metabolism in human liver cytosol assessed as (R)-4-fluoro-5-(6-(2-hydroxypropoxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-4-yloxy)-1H-indole-2-carboxylic acid formation at 2 uM for 60 mins by LC/MS analysis
Drug metabolism in human liver cytosol assessed as (R)-1-(4-(4-fluoro-2-(hydroxymethyl)-1H-indol-5-yloxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-6-yloxy)propane-2-sulfonic acid formation at 2 uM for 60 mins by LC/MS analysis in presence of PAPS
Drug metabolism in human liver cytosol assessed as (R)-4-fluoro-5-(5-methyl-6-(2-sulfopropoxy)pyrrolo[1,2-f][1,2,4]triazin-4-yloxy)-1H-indole-2-carboxylic acid formation at 2 uM for 60 mins by LC/MS analysis in presence of PAPS
Drug metabolism in human liver microsomes assessed as (R)-4-fluoro-5-(6-(2-hydroxypropoxy)-5-methylpyrrolo[1,2-f][1,2,4]triazin-4-yloxy)-1H-indole-2-carboxylic acid formation at 2 uM for 60 mins by LC/MS analysis in presence of NADPH